Chi-Med Starts China Phase I/II Trial of Novel FGFR Inhibitor

03:50 EDT 23 Jun 2017 | ChinaBio Today

Hutchison China MediTech (Chi-Med) has dosed the first patient in a China Phase I/II trial of HMPL-453. HMPL-453 is a small molecule inhibitor of fibroblast growth factor receptor (FGFR). Earlier this year, HMPL-453 began its first Phase I trial in Australia, the eighth Chi-Med molecule to begin clinical trials. Last week, Chi-Med reported the CFDA accepted the company's New Drug Application for its lead drug, fruquintinib, a VEGFR inhibitor, indicated for colorectal cancer. More details....

Stock Symbols: (AIM/NSDQ: HCM)

Share this with colleagues:  

Original Article: Chi-Med Starts China Phase I/II Trial of Novel FGFR Inhibitor


More From BioPortfolio on "Chi-Med Starts China Phase I/II Trial of Novel FGFR Inhibitor"

Quick Search


Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...